Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
4 affiliations
- 1Internal Medicine Department, Parma University Hospital , ,
- 2Emerging Infectious Disease and High Contagiousness Unit P.O. D. Cotugno-AORN Ospedali dei Colli , ,
- 3Coordination of the Regional Health System, General Directorate for Health Protection , ,
- 4Internal Medicine Ward “P.O. Santa Maria delle Grazie” , ,
Abstract
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major cause of morbidity and mortality worldwide. The introduction of direct oral anticoagulants (DOACs) has transformed the management of VTE by providing effective and convenient alternatives to vitamin K antagonists. However, despite their favorable efficacy–safety profile, clinically relevant bleeding, treatment individualization, and the management of patients with competing thrombotic and hemorrhagic risks remain important unmet clinical needs. Contemporary VTE management increasingly requires a personalized approach integrating clinical characteristics, comorbidities, biomarkers, and real-world evidence to optimize anticoagulant selection, treatment intensity, and duration. Large prospective registries have expanded our understanding of VTE across heterogeneous clinical settings, including cancer-associated thrombosis, postoperative VTE, incidental and subsegmental pulmonary embolism, and other high-risk populations frequently underrepresented in randomized clinical trials. In parallel, emerging prognostic tools, including D-dimer, hemoglobin, inflammatory indices, lipid-related biomarkers, and machine-learning-based prediction models, are contributing to a more refined assessment of thrombotic and bleeding risk. These emerging therapies are being evaluated as potential strategies to reduce bleeding while maintaining antithrombotic efficacy; however, recent phase III findings have demonstrated heterogeneous efficacy across clinical indications, emphasizing that their future role is likely to be indication-specific. This narrative review examines the current role of DOACs in VTE management, discusses the clinical and biological determinants of individualized anticoagulant therapy, and critically appraises the evolving and heterogeneous evidence for Factor XI inhibition as a potential future anticoagulant strategy.
Related
- CO090 | DIRECT ORAL ANTICOAGULANTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE INHERITED THROMBOPHILIA: A REAL-WORLD MULTICENTER STUDY
- Long-Term Effectiveness and Safety of Direct Oral Anticoagulants in Japanese Patients With Venous Thromboembolism ― Extended Follow-up Results From the KUROSIO Study ―
- Risk factors of major bleeding associated with direct oral anticoagulant treatment in patients with venous thromboembolism: a systematic review and meta-analysis
- Trends in Direct Oral Anticoagulant Use for Cancer-Associated Venous Thromboembolism
- PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
BibTeX
@article{siniscalchi2026personalized,
title = {{Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition}},
author = {Carmine Siniscalchi and Alessandro Perrella and Ugo Trama and Manuela Basaglia and Francesca Futura Bernardi and Pierpaolo Di Micco},
journal = {Frontiers in pharmacology},
year = {2026},
month = sep,
doi = {10.3389/fphar.2026.1959476},
url = {https://europepmc.org/article/PMC/PMC13661385},
note = {CC BY},
}
RIS
TY - JOUR
TI - Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
AU - Carmine Siniscalchi
AU - Alessandro Perrella
AU - Ugo Trama
AU - Manuela Basaglia
AU - Francesca Futura Bernardi
AU - Pierpaolo Di Micco
PY - 2026
DA - 2026/09/30
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1959476
UR - https://europepmc.org/article/PMC/PMC13661385
AB - Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major cause of morbidity and mortality worldwide. The introduction of direct oral anticoagulants (DOACs) has transformed the management of VTE by providing effective and convenient alternatives to vitamin K antagonists. However, despite their favorable efficacy–safety profile, clinically relevant bleeding, treatment individualization, and the management of patients with competing thrombotic and hemorrhagic risks remain important unmet clinical needs. Contemporary VTE management increasingly requires a personalized approach integrating clinical characteristics, comorbidities, biomarkers, and real-world evidence to optimize anticoagulant selection, treatment intensity, and duration. Large prospective registries have expanded our understanding of VTE across heterogeneous clinical settings, including cancer-associated thrombosis, postoperative VTE, incidental and subsegmental pulmonary embolism, and other high-risk populations frequently underrepresented in randomized clinical trials. In parallel, emerging prognostic tools, including D-dimer, hemoglobin, inflammatory indices, lipid-related biomarkers, and machine-learning-based prediction models, are contributing to a more refined assessment of thrombotic and bleeding risk. These emerging therapies are being evaluated as potential strategies to reduce bleeding while maintaining antithrombotic efficacy; however, recent phase III findings have demonstrated heterogeneous efficacy across clinical indications, emphasizing that their future role is likely to be indication-specific. This narrative review examines the current role of DOACs in VTE management, discusses the clinical and biological determinants of individualized anticoagulant therapy, and critically appraises the evolving and heterogeneous evidence for Factor XI inhibition as a potential future anticoagulant strategy.
SN - 1663-9812
ER -